Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Nazeer Hussain Khan,Maria Mir,Ebenezeri Erasto Ngowi,Ujala Zafar,Muhammad Mahtab Aslam Khan Khakwani,Saadullah Khattak,Yuan-Kun Zhai,En-She Jiang,Meng Zheng,Shao-Feng Duan,Jian-She Wei,Dong-Dong Wu,Xin-Ying Ji

DOI: https://doi.org/10.3389/fbioe.2021.630055

IF: 5.7

2021-04-09

Frontiers in Bioengineering and Biotechnology

Abstract:Alzheimer’s disease (AD) is a devastating disease of the aging population characterized by the progressive and slow brain decay due to the formation of extracellular plaques in the hippocampus. AD cells encompass tangles of twisted strands of aggregated microtubule binding proteins surrounded by plaques. Delivering corresponding drugs in the brain to deal with these clinical pathologies, we face a naturally built strong, protective barrier between circulating blood and brain cells called the blood–brain barrier (BBB). Nanomedicines provide state-of-the-art alternative approaches to overcome the challenges in drug transport across the BBB. The current review presents the advances in the roles of nanomedicines in both the diagnosis and treatment of AD. We intend to provide an overview of how nanotechnology has revolutionized the approaches used to manage AD and highlight the current key bottlenecks and future perspective in this field. Furthermore, the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.

multidisciplinary sciences